Abstract: A high molecular weight (“HMW”) protein of Chlamydia, the amino acid sequence thereof, and antibodies that specifically bind the HMW protein are disclosed as well as the nucleic acid sequence encoding the same. Also disclosed are prophylactic and therapeutic compositions, comprising the HMW protein, a fragment thereof, or an antibody that specifically binds the HMW protein or a protein thereof, or the nucleotide sequence encoding the HMW protein or a fragment thereof, including vaccines.
Abstract: ASP2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ASP2 polypeptides and polynucleotides in the design of protocols for the treatment of Alzheimer's Disease, cancer, and prohormone processing, among others, and diagnostic assays for such conditions.
Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the ? secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
Type:
Grant
Filed:
April 12, 2000
Date of Patent:
March 15, 2005
Assignee:
Pharmacia & Upjohn Company
Inventors:
Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
Abstract: Analogs of FK506 that do not bind FKBP-12 have been found to effectively promote nerve cell growth and regeneration, thereby speeding functional recovery of damaged nervous tissue and axonal regeneration without causing immunosuppression.
Abstract: The present application relates to nucleotide sequences which regulate the biosynthesis of the flagella proteins Helicobacter pylori, to the proteins encoded by these sequences and to aflagellate bacterial strains. The invention also relates to the use of these means for detecting an infection due to H.pylori or for protecting against such an infection.
Type:
Grant
Filed:
January 29, 1998
Date of Patent:
January 4, 2005
Assignee:
Institut Pasteur and Institut National de la Sante et de la Recherche Medicale
Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
Type:
Grant
Filed:
April 12, 2000
Date of Patent:
November 30, 2004
Assignee:
Pharmacia & Upjohn Company
Inventors:
Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
Abstract: The present invention provides methods and compositions for the diagnosis of Alzheimer's disease. In particular, the present invention provides modified beta-amyloid peptides, antibodies that specifically bind to the modified beta-amyloid peptides, and methods for using these compositions in the diagnosis of Alzheimer's disease, as well as methods to monitor treatment and/or disease progression of Alzheimer's disease in patients. The present invention also provides compositions and methods useful in research involving amyloid precursor protein (APP) metabolism and Alzheimer's disease.
Abstract: Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.
Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.
Type:
Grant
Filed:
June 16, 1994
Date of Patent:
October 5, 2004
Assignee:
Curis, Inc.
Inventors:
David C. Rueger, Thangavel Kuberasampath, Hermann Oppermann, Roy H. L. Pang, Charles M. Cohen
Abstract: The present invention relates to isolated polypeptides having aminopeptidase activity and isolated nucleic acid sequences encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the polypeptides.
Type:
Grant
Filed:
May 15, 1998
Date of Patent:
October 5, 2004
Assignee:
Novozymes Biotech, Inc.
Inventors:
Alexander Blinkovsky, Kimberly Brown, Elizabeth Golightly, Tony Byun
Abstract: The present invention provides methods of reducing cellular production of amyloid beta (A&bgr;) from amyloid precursor protein (APP) by reducing Asp2 transcription or translation in cells.
Type:
Grant
Filed:
April 12, 2000
Date of Patent:
September 28, 2004
Assignee:
Pharamcia & Upjohn Company
Inventors:
Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
Abstract: The invention provides a method for stimulating nerve growth, which also includes nerve regeneration, by contacting nerve cells with human Neural Plakophilin Related Armadillo Protein (hNPRAP). In a specific embodiment, hNPRAP causes the development of numerous long, cellular extensions, which are similar to axonal sprouting observed during neuronal regeneration and synapse formation. The invention further relates to pharmaceutical compositions comprising an hNPRAP, or alternatively a gene therapy vector that expresses an hNPRAP. Also provided are methods for identifying substances that modulate expression of hNPRAP.
Type:
Grant
Filed:
February 9, 2000
Date of Patent:
August 31, 2004
Assignee:
The Governing Council of The University of Toronto
Inventors:
Peter H. St. George-Hyslop, Paul E. Fraser
Abstract: The invention provides a cDNA which encodes human presenilin variant. It also provides for the use of the cDNA and protein in the diagnosis, prognosis, treatment and evaluation of therapies for cancer or neurodegenerative or immune disorders. The invention further provides vectors and host cells for the production of the protein and transgenic model systems.
Type:
Grant
Filed:
June 29, 2001
Date of Patent:
August 31, 2004
Assignee:
Incyte Corporation
Inventors:
Chandra Arvizu, Lynn E. Murry, Matthew R. Kaser
Abstract: Disclosed herein are aggregating amyloid A&bgr; peptides which are covalently bonded (for example, at a cysteine amino acid residue) to a fluorescent label, and methods for their use.
Type:
Grant
Filed:
June 5, 2003
Date of Patent:
August 3, 2004
Assignee:
The Regents of the University of California
Inventors:
Charles Glabe, William Garzon Rodriguez
Abstract: Peptides have been discovered which are capable of binding to and internalizing with the human transferrin receptor (hTfR). The sequences HAIYPRH (Seq. ID No. 1) and THRPPMWSPVWP (Seq. ID No. 2) are capable of binding to and internalizing with the human transferrin receptor. When these molecules were fused with other molecules, the fusion product was internalized in cells expressing hTfR. The sequences have use for targeting other peptides and proteins into cells expressing hTfR.
Type:
Grant
Filed:
November 29, 2001
Date of Patent:
June 1, 2004
Assignee:
The UAB Research Foundation
Inventors:
Jeffrey A. Engler, Jae Hwy Lee, James F. Collawn, Bryan A. Moore
Abstract: Human G-protein chemokine receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.
Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
Type:
Grant
Filed:
April 12, 2000
Date of Patent:
May 18, 2004
Assignee:
Pharmacia & Upjohn Company
Inventors:
Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
Type:
Grant
Filed:
September 15, 2000
Date of Patent:
May 11, 2004
Assignee:
NsGene A/S
Inventors:
Teit E. Johansen, Nikolaj Blom, Claus Hansen
Abstract: Disclosed are therapeutic treatment methods, compositions and devices for maintaining neural pathways in a mammal, including enhancing survival of neurons at risk of dying, inducing cellular repair of damaged neurons and neural pathways, and stimulating neurons to maintain their differentiated phenotype. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration.
Type:
Grant
Filed:
September 25, 1997
Date of Patent:
April 20, 2004
Assignee:
Curis, Inc.
Inventors:
David C. Rueger, Kuber T. Sampath, Hermann Oppermann, Roy H. L. Pang, Charles M. Cohen
Abstract: This invention provides an isolated DNA or gene that is responsible for Parkinson's disease and is useful in diagnosing and treating the disease etc.
The isolated DNA or gene according to this invention comprises a full-length base sequence according to the sequence ID. No. 1 or 2, or a partial sequence thereof, or a base sequence hybridizable thereto or hybridizable with a complemental strand thereof, and being associated with Parkinson's disease.